newsfilter
← Latest News
Business Wire·

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor's proven clinical benefit in both NSCLC and ES-SCLC Early data from investigational HPK1 inhibitor BGB-26808, in